This review summarises important pharmacological and clinical characteristics of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Independent expert commentary by Professor Bruce Taylor a clinical academic neurologist and a graduate of the University of Tasmania, who completed neurology training in Perth before completing fellowship training at the Mayo Clinic Rochester Minnesota. He currently holds a personal chair at the Menzies Institute for Medical Research University of Tasmania and a conjoint appointment with the Royal Hobart Hospital.
Please login below to download this issue (PDF)